WCTF.org Transplant News

DETROIT, April 14 /PRNewswire-USNewswire/ -- A unique global conference focusing on the future of healthcare will convene in Detroit June 8 - 10, 2009. The HealthQuake Summit will present an opportunity for leaders from around the world to gather and explore the ongoing and future seismic "tremors" in the healthcare industry in the areas of business, policy, and science/technology that will make the industry virtually unrecognizable in the coming years.

Featured speaker will be world-renowned surgeon Dr. Jean-Michel Dubernard of the Edouard Herriot Hospital in Lyon, France. Dr. Dubernard is associated with many medical firsts, including the first hand transplant (1998) and the first human face transplant (2005). Partnering agencies for the Summit include the Detroit Medical Center (dmc.org), the World Technology Network (wtn.net), the Institute for Alternative Futures (altfutures.com), and the American Association for the Advancement of Science (AAAS)/Science magazine (aaas.org).

According to Executive Producer/Director, James P. Clark, HealthQuake represents a truly unique opportunity as the one of the most crucial industries in the world adjusts to the ramifications of such seismic shifts as simplification; automation and robotics; postmodern medicine; globalization; the defeat of chronic disease, and longevity. "Healthcare over the course of the coming years of the early 21st Century will be nothing like it is today. The healthcare landscape will be unrecognizable one way or another," Clark said. "HealthQuake will help us all be prepared and show us how to best take advantage of the enormous changes already in process or soon to come."

The HealthQuake Summit will be held at the Detroit Marriott June 8 - 10, 2009. For more information, visit www.healthquake.org

First Call Analyst:
FCMN Contact:

Source: Detroit Medical Center

CONTACT: Annessa Carlisle of Detroit Medical Center, +1-313-520-8697

Web Site:

http://www.healthquake.org/

-------
Profile: Transplant News

HOUSTON, April 14 /PRNewswire-USNewswire/ -- Physician scientists at the Texas Heart Institute (THI) at St. Luke's Episcopal Hospital announced they have begun the world's first clinical trial to treat heart attack patients with a special type of stem cell to promote better healing and to prevent congestive heart failure, which many patients develop following a heart attack.

Almost six million Americans have congestive heart failure, a progressive form of cardiovascular disease that inhibits the heart from pumping blood throughout the body, and 550,000 new cases are diagnosed each year. About half of these patients die within five years after receiving a diagnosis of severe heart failure.

Stem cell transplantation offers new hope for treating heart failure. Stem cells are "generic" cells that can regenerate themselves and develop into specialized cells, such as cardiac cells. In stem cell therapy, stem cells are typically removed from another part of the patient's body -- usually the bone marrow or the blood, both of which contain a variety of stem cell types. The cells are then transplanted into the heart, where they can lead to the growth of new heart muscle and blood vessels to replace damaged tissues.

The special stem cells used in this study, known as mesenchymal precursor stem cells, are allogenic, meaning that they have been taken from the bone marrow of a healthy donor and grown in cultures to provide a plentiful supply. These cells, which are injected directly into the heart with a special catheter, appear not to provoke rejection by the recipient or cause inflammation.

The first patient to receive the treatment is a 65-year-old man. The man's heart attack was treated with angioplasty to open the obstructed vessel, and he received a stent, a spring-like device, to keep the vessel open. He had the stem cell procedure in the catheterization laboratory ten days after having his heart attack, and he was discharged from the hospital two days after receiving this experimental treatment.

"Our pre-clinical trials have established that ten days after the heart attack is the optimal time to give this treatment. The heart is still inflamed in the days just after a heart attack. If we wait too late, the heart will have too much scar tissue and its ability to pump will already be compromised," said Emerson Perin, M.D., Ph.D. Dr. Perin is the director of the Texas Heart Institute's Stem Cell Center and he was recently appointed Director of Clinical Research for Cardiovascular Medicine at THI.

This randomized Phase I trial will include 25 patients in three phases in which the patient receives 25, 75 or 150 million stem cells. Physicians use a 3-D imaging technology which maps the electrical and mechanical function of the left ventricle, the main pumping chamber of the heart. The stem cells are injected into damaged but still viable areas of the heart muscle. The study is sponsored by Angioblast Systems, a company which provides the proprietary cells.

"This is a major milestone in the adult stem cell research we began eight years ago. Our challenge remains to identify the very best types of stem cells, refine our delivery techniques, and establish the most effective doses of stem cells. We also have much work to do in understanding the molecular mechanisms by which stem cells differentiate into specific organs and tissue," said James Willerson, M.D., president-elect and medical director of the Texas Heart Institute at St. Luke's. He is also President of The University of Texas Health Science Center at Houston.

Dr. Willerson made the point that every person is a product of two cells which develop into billions of stem cells that have the innate ability to form our bodies.

"All of us have stem cells in our bodies, just not in sufficient numbers to perform the healing we need. I believe we were meant to learn of the powerful potential of stem cells and build on it. In the coming years, this could be an accepted stem cell therapy at hospitals. Ultimately, stem cell research could give us the ability to regenerate whole hearts," said Dr. Willerson.

Drs. Perin and Willerson and their team have developed a network of several hospitals to identify patients who may fit the criteria to be enrolled in this trial.

"We're already seeing promising results from treating patients with severe heart failure with their own stem cells. With this study, we hope to find a way to help patients before they get so sick," said Dr. Perin.

For more information about this clinical trial or others underway at the Texas Heart Institute, contact the Stem Cell Center at 866-924-7836 or email stemcell@heart.thi.tmc.edu. There is also information on all the trials at www.texasheart.org.

First Call Analyst:
FCMN Contact:

Source: Texas Heart Institute

CONTACT: Kathy Watson of Texas Heart Institute, +1-832-355-6569,
kwatson@heart.thi.tmc.edu or Melinda Muse of St. Luke's Episcopal Hospital,
+1-832-355-3040, mmuse@sleh.com

Web Site:

http://www.stlukestexas.com/
http://www.texasheart.org/

-------
Profile: Transplant News

Data in Cell Transplantation Demonstrates Capacity of Menstrual Stem Cells

OLDSMAR, Fla., April 14 /PRNewswire-FirstCall/ -- Cryo-Cell International, Inc. today announced results of a study published this month in Cell Transplantation showing that stem cells found in menstrual blood proliferate rapidly and have significant potential to develop into multiple cell types. Menstrual stem cells offer an easily accessible, non-controversial and renewable stem cell source, and these findings could mean these cells have the potential to one day treat a host of diseases.

The study, "Multipotent Menstrual Blood Stromal Stem Cells: Isolation, Characterization and Differentiation," was conducted by researchers at Cryo- Cell International who originally discovered the stem cells. According to the study, the stem cells in menstrual blood, known as MenSCs, are stromal stem cells, meaning they have the capability to differentiate into important cells, such as such as bone, cartilage, fat, nerve and cardiogenic cells. The study also found that the cells divided rapidly and plentifully, indicating a possible therapeutic value.

With additional studies of the cells in a variety of categories, the use of these cells may lead to treatments for a number of serious diseases, such as osteoporosis, stroke, Alzheimer's and Parkinson's disease. The cells may even one day be used for customized anti-aging or sports medicine treatments.

"These findings demonstrate that this novel cell population is adequately potent to one day be a routinely and safely isolated source of stem cells," said Julie Allickson, Ph.D., study investigator and Vice President, Laboratory Operations, Research and Development at Cryo-Cell International, Inc. "Clinical trials are now underway to test the safety and efficacy of MenSCs in animal models for diabetes, neurodegenerative and cardiovascular regenerative therapies."

"As we research several sources of stem cells for their potential therapeutic benefits, we look for cells to emulate embryonic stem cells in that they have the ability to grow rapidly and to become many different types of cells," said Dr. Camillo Ricordi, director of the Cell Transplant Center and the Diabetes Research Institute at the University of Miami. "These menstrual stem cells could have several of the embryonic stem cell attributes, in addition to being easily extracted, not controversial and renewable."

During the study, the investigators analyzed shed menstrual blood and tissue to identify MenSCs. The samples were obtained using a menstrual cup and transferred to a laboratory for processing. At the lab, the cells were quality control-tested and grown in culture to allow for expansion and to assess their growth capabilities. Further analyses were conducted to assess the cells' ability to differentiate into new cell lines, in order to determine which diseases the cells may be used to treat. The average cell collection from a sample of menstrual blood was approximately five million, of which 75 percent of the cells were considered viable. Importantly, the cells rapidly expanded at a doubling rate of 24-36 hours, starting with 50,000 cells on day one and culminating into 48 million cells in less than one month.

"This promising study is the first of many we are conducting in collaboration with leading researchers and institutions with the ultimate goal of using these stem cells to develop groundbreaking future treatments," said Mercedes Walton, Cryo-Cell's Chairman and CEO. "These initial findings offer scientific support and validation for women who are interested in preserving their own menstrual blood stem cells for potential future benefit."

Based on the results of the study, Cryo-Cell is pursuing further research into menstrual stem cells. Cryo-Cell is organizing a number of research and development agreements in efforts to develop promising regenerative therapies utilizing C'elle technology in cardiology, diabetes and neurological diseases. Results from these studies are expected in the next year. The Company is actively seeking to expand its portfolio of research collaborations with scientists worldwide interested in studying this novel stem cell population for regenerative therapeutic development. Cryo-Cell's C'elle(SM) service, which was introduced in November, 2007, is the first available product that enables women to collect menstrual flow containing stem cells, which can then be cryogenically preserved in a manner similar to stem cells from umbilical cord blood.

About Cryo-Cell International, Inc. (BULLETIN BOARD: CCEL.OB)

Based in Oldsmar, Florida, with over 150,000 clients worldwide, Cryo-Cell is one of the largest and most established family cord blood banks. ISO 9001: 2000 certified and accredited by the AABB, Cryo-Cell operates in a state-of- the-art Good Manufacturing Practice and Good Tissue Practice (cGMP/cGTP)- compliant facility. Cryo-Cell is a publicly traded company. OTC Bulletin Board Symbol: CCEL. For more information, please call 1-800-STOR-CELL (1-800- 786-7235) or visit http://www.cryo-cell.com/.

Forward-Looking Statement

Statements wherein the terms "believes", "intends", "projects" or "expects" as used are intended to reflect "forward-looking statements" of the Company. The information contained herein is subject to various risks, uncertainties and other factors that could cause actual results to differ materially from the results anticipated in such forward-looking statements or paragraphs, many of which are outside the control of the Company. These uncertainties and other factors include the uncertainty of market acceptance of any potential service offerings relating to types of stem cells other than cord blood stem cells, including the C'elle service, given that menstrual stem cells and other new stem cells have not yet been used in human therapies, and treatment applications using such stem cells are not likely to be developed and commercialized for many years and are subject to further research and development; the need for additional development and testing before determining the ultimate commercial value of the Company's intellectual property relating to the menstrual stem cells; the need to complete certain developments, including completion of clinical validation and testing, before any new process other than C'elle can be commercialized, and the Company's development of its final business and economic model in offering any such service; any adverse effect or limitations caused by recent increases in government regulation of stem cell storage facilities; any increased competition in our business; any decrease or slowdown in the number of people seeking to store umbilical cord blood stem cells or decrease in the number of people paying annual storage fees; any adverse impacts on our revenue or operating margins due to the costs associated with increased growth in our business, including the possibility of unanticipated costs relating to the operation of our new facility; any technological breakthrough or medical breakthrough that would render the Company's business of stem cell preservation obsolete; any material failure or malfunction in our storage facilities; any natural disaster such as a tornado, other disaster (fire) or act of terrorism that adversely affects stored specimens; the costs associated with defending or prosecuting litigation matters and any material adverse result from such matters; decreases in asset valuations; any continued negative effect from adverse publicity in the past year regarding the Company's business operations; any negative consequences resulting from deriving, shipping and storing specimens at a second location; and other risks and uncertainties. The foregoing list is not exhaustive, and the Company disclaims any obligations to subsequently revise any forward-looking statements to reflect events or circumstances after the date of such statements. Readers should carefully review the risk factors described in other documents the Company files from time to time with the Securities and Exchange Commission, including the most recent Annual Report on Form 10-KSB, Quarterly Reports on Form 10-QSB and any Current Reports on Form 8-K filed by the Company.

Contact:
General Media Inquiries
Kristin O'Neill
312-233-1295
kristin.oneill@edelman.com

Financial Media Inquiries
Mona Walsh
212-704-4598
mona.walsh@edelman.com

First Call Analyst:
FCMN Contact: Kristin.ONeill@edelman.com

Source: Cryo-Cell International, Inc.

CONTACT: media, Kristin O'Neill, +1-312-233-1295,
kristin.oneill@edelman.com, or financial, Mona Walsh, +1-212-704-4598,
mona.walsh@edelman.com, both of Edelman, for Cryo-Cell International, Inc.

Web site: http://www.cryo-cell.com/

-------
Profile: Transplant News

Motor Neuron Disease is Leading Cause of Death for Infants

WESTBOROUGH, Mass., April 14 /PRNewswire-FirstCall/ -- Genzyme Genetics, a business unit of Genzyme Corporation (NASDAQ:GENZ), announced today that it is the first national laboratory specializing in reproductive testing to provide population carrier and prenatal diagnostic testing for spinal muscular atrophy (SMA), the most common inherited cause of infant mortality. This test will enable couples who are planning a pregnancy, or who are already pregnant, to determine if they are carriers and at risk of having a baby with SMA.

"With no cure currently available, the best method for preventing SMA is carrier testing," said Deborah Heine, Executive Director of the Claire Altman Heine Foundation, a nonprofit organization devoted to promoting pan-ethnic SMA carrier screening. "The availability of this test will now allow individuals and couples of childbearing age to make more informed reproductive decisions regarding the risk of SMA and, hopefully, prevent the suffering of losing a child to this devastating disease."

Deborah and Chris Heine lost their daughter, Claire, to SMA at the age of 9 months. The Heines were not offered SMA carrier screening during a pre-conception consultation and have worked since that time to implement pan-ethnic SMA carrier screening.

The Genzyme Genetics SMA test offers results in approximately 7 to 11 days and is expected to have an approximately 94 percent detection rate of carriers overall and approximately the same detection rate for the most common and severe types of SMA in affected fetuses. SMA is characterized by progressive muscle degeneration of motor neurons, resulting in severe muscle weakness. In 60-70 percent of cases, children with SMA die from respiratory failure by age two.

Greater than 94% of SMA carriers have a deletion of one SMN1 gene. Genzyme's new test utilizes quantitative PCR (polymerase chain reaction), a technology that can determine the number of SMN1 genes. An individual with one SMN1 gene is a carrier of SMA; a fetus with no SMN1 genes will be affected with SMA. SMA is caused when both parents have only one SMN1 gene. Approximately one in 41 people is a carrier of the SMA-causing gene, resulting in an incidence rate of 1 in 6,000-10,000 births. If both parents are found to be carriers, prenatal diagnosis by chorionic villi sampling or amniocentesis is available.

"Carriers of SMA have no symptoms of the disease and rarely have a family history of SMA," says Stirling M. Puck, M.D., of Genzyme Genetics. "Therefore, carrier screening for this disease should be widely available to ensure people are aware of their chances of having a child with SMA. Advancements in technology have led to the ability to detect approximately 94 percent of carriers, and then to offer prenatal testing to at-risk parents; these advancements will help couples planning a pregnancy make informed decisions."

The rights to perform SMN1 testing are provided under license from Athena Diagnostics, part of Thermo Fisher Scientific Inc.

About SMA

SMA is an autosomal recessive disease which causes severe weakness in the muscles that control breathing, swallowing, head and neck control, walking and crawling. After cystic fibrosis, which is routinely screened for in the general population, SMA is the second most common lethal autosomal recessive disease in the United States. Other examples of autosomal recessive conditions include sickle cell anemia, and Tay-Sachs disease.

About Genzyme Genetics

Genzyme Genetics is a leading, nationwide provider of high quality genetic testing and genetic counseling services for physicians and their patients. With laboratories and counseling facilities located across the U.S., Genzyme Genetics offers extensive reproductive and cancer testing services, supported by innovative technology and a commitment to quality service and trusted information. Genzyme Genetics is a business unit of Genzyme Corporation.

In addition to SMA carrier testing and prenatal diagnosis, Genzyme offers a broad carrier test menu including cystic fibrosis testing with 97 mutations, fragile X testing and 11 carrier tests for the Ashkenazi Jewish population; an industry-leading cytogenetics program; an extensive maternal serum screening program (which includes first trimester, integrated and second trimester screening); and an innovative infertility testing program.

About Genzyme

One of the world's leading biotechnology companies, Genzyme is dedicated to making a major positive impact on the lives of people with serious diseases. Since 1981, the company has grown from a small start-up to a diversified enterprise with more than 10,000 employees in locations spanning the globe and 2007 revenues of $3.8 billion. In 2007, Genzyme was chosen to receive the National Medal of Technology, the highest honor awarded by the President of the United States for technological innovation.

With many established products and services helping patients in nearly 90 countries, Genzyme is a leader in the effort to develop and apply the most advanced technologies in the life sciences. The company's products and services are focused on rare inherited disorders, kidney disease, orthopaedics, cancer, transplant, and diagnostic testing. Genzyme's commitment to innovation continues today with a substantial development program focused on these fields, as well as immune disease, infectious disease, and other areas of unmet medical need.

Genzyme's press releases and other company information are available at http://www.genzyme.com/ and by calling Genzyme's investor information line at 1-800-905-4369 within the United States or 1-678-999-4572 outside the United States.

Media Contact: Investor Contact:
Sarah Millerick Leah Rosenberger
(617) 768-6438 (617) 768-6602

First Call Analyst:
FCMN Contact:

Source: Genzyme Corporation

CONTACT: Media, Sarah Millerick, +1-617-768-6438, or Investors, Leah
Rosenberger, +1-617-768-6602, both of Genzyme Corporation

Web site:

http://www.genzyme.com/

Company News On-Call:

http://www.prnewswire.com/comp/104284.html

-------
Profile: Transplant News

Soft tissue navigation systems to expand the $200 million surgical navigation market, according to Millennium Research Group

WALTHAM, Mass., April 14, 2008 /PRNewswire/ -- According to Millennium Research Group's US Markets for Surgical Navigation Systems 2008 report, the surgical navigation market was worth almost $200 million in 2007, and will grow rapidly over the next five years. This growth will be partly facilitated by soft tissue navigation, an emerging technology that allows surgeons to track their instruments inside organs such as the heart or liver using image guidance in the operating field.

Soft tissue navigation systems are anticipated to revolutionize risky procedures such as vascular bypass surgery, valve replacement, arrhythmia treatment, tumor removal, and living donor organ transplants. These systems will boost the number of patients who can be treated with liver transplants in particular, increasing the survival rate of patients with diseases like hepatitis or cirrhosis. In comparison with standard organ transplant surgery, where patients can wait months or years for a matching donor, soft tissue navigation enables safer removal and transplantation of living donor organs, ensuring that the donor retains sufficient healthy tissue to regenerate their liver.

"Just as surgical navigation systems transformed risky neurosurgery procedures in the last decade, soft tissue navigation systems will be instrumental for improving clinical outcomes in difficult cardiovascular and abdominal surgery," says Sarah Leonard, Analyst at Millennium Research Group. "Pathfinder Therapeutics' SurgiSight Linasys recently gained clearance for all open liver procedures, and Novadaq Technologies' SPY was just approved for use in organ transplant surgery. Other companies focusing on cardiovascular disease are expecting to gain approval for surgical intervention over the next few months."

Initial adopters of soft tissue navigation will be large surgical centers, such as academic hospitals and high-volume heart and cancer centers. If these institutions successfully enhance patient safety and enable high-risk patients to receive potentially life-saving procedures by using soft tissue navigation systems, other surgical facilities will follow suit and adopt the technology.

The Surgical Navigation Systems 2008 report covers the neurosurgery, spine, ear, nose, and throat (ENT), and orthopedics navigation system markets. Industry competitors include Aesculap, BrainLAB, Hansen Medical, Medtronic Navigation, Novadaq Technologies, ORTHOsoft, Pathfinder Therapeutics, Stereotaxis, and Stryker Navigation.

About Soft Tissue Navigation Systems

Navigated abdominal surgery systems, used in soft tissue navigation, scan the surface of the liver using a laser range scanner to gather over 20,000 positioning points. These points are matched to a preoperative computed tomography scan and used to create a 3-D operative model of the organ, which allows surgeons to track the procedure around and through the tissue. Another soft tissue navigation technology for organ transplants and vascular bypasses uses fluorescent dyes and near-infrared spectroscopy to track blood flow within an organ or tissue.

About Millennium Research Group

Millennium Research Group (www.MRG.net), a Decision Resources, Inc. company (www.DecisionResources.com), is the global authority on medical technology market intelligence and a leading provider of strategic information to the health care sector. Focused solely on the medical device, pharmaceutical, and biotechnology industries, the company provides its clients with the benefits of its specialized industry expertise through published reports and customized consulting services.

All company, brand, or product names contained in this document may be
trademarks or registered trademarks of their respective holders.

For more information, contact:

Amy Krohn
Millennium Research Group
416-364-7776 x101
akrohn@mrg.net

Source: Millennium Research Group

CONTACT: Amy Krohn of Millennium Research Group,
+1-416-364-7776, ext. 101, akrohn@mrg.net

Web site:

http://www.mrg.net/

-------
Profile: Transplant News

ASCOT, England, April 14/PRNewswire/ -- Therakos, Inc., a pioneer for more than 20 years in immune cell therapy,
announced receipt of a CE Mark in Europe for THERAKOS(TM) CELLEX(TM)
Photopheresis System, a therapy for the treatment of patients with
immune-mediated diseases such as acute or chronic graft-versus-host disease
(GvHD) and cutaneous T-cell lymphoma (CTCL). THERAKOS(TM) CELLEX(TM)
Photopheresis System is the next generation in a product line that offers the
only validated, automated and integrated systems that are CE Marked to
perform extracorporeal photopheresis (ECP).

(Photo: http://www.newscom.com/cgi-bin/prnh/20080414/300639)

The new THERAKOS(TM) CELLEX(TM) Photopheresis System offers state-of-the
art technology in a single, integrated, closed system device that allows a
sole operator to customize a patient's treatment and immediately adjust
parameters to respond to changes in the patient's condition. A closed system
offers the benefits of reduced risks for infection and infusion errors. The
THERAKOS(TM) CELLEX(TM) Photopheresis System offers new features that include
optimal fluid and blood volume management, user-friendly operator interface
and automation with the option for simple manual intervention when needed.
These features represent sophisticated treatment options that can offer the
benefit of shorter overall treatment time and require lower extra corporeal
volume, both important factors for patients and health care professionals.

The European Organization for Research and Treatment of Cancer (EORTC)
recommends ECP among the potential therapies to be considered for the
treatment of CTCL, a slowly progressive form of cancer.

About Extracorporeal Photopheresis (ECP)

ECP is a therapeutic procedure performed outside the body using the
THERAKOS(TM) CELLEX(TM) Photopheresis System to withdraw a volume of whole
blood that is then centrifuged to separate the white blood cells from the red
blood cells and plasma. The red blood cells and plasma are immediately
reinfused into the patient. The white blood cells are treated with
methoxsalen, a drug used to treat some cutaneous lymphomas and skin disorders
in conjunction with exposure to ultraviolet light. The treated white blood
cells are then reinfused into the patient. Clinical studies suggest that the
treated white blood cells, when reinfused into the body, may bring the immune
system into balance by controlling the activity of overactive immune cells.

About Graft-Versus-Host Disease (GvHD) and Cutaneous T-Cell Lymphoma
(CTCL)

Graft-versus-host disease (GvHD) occurs in allogeneic bone marrow
transplants, which involve transplanted cells from a donor other than the
patient. It is a life-threatening complication in which the new donor cells
attack the patient's organs and tissues. The result is an inflammatory
reaction targeted against the skin, mouth, lungs and liver that results in
severe tight skin, mouth ulcers, difficulty breathing, liver failure and in
severe cases, death. Acute GvHD starts within the first 3 months after
transplant. Chronic GvHD starts more than three months after transplant, and
can last for as long as three years. According to the International Center
for Blood and Marrow Transplant Research, of the 14,000 allogeneic
transplants performed worldwide, approximately 50 percent of patients will
develop acute GvHD, and another 50 percent to 70 percent will develop chronic
GvHD.

Cutaneous T-cell lymphoma (CTCL) is a slowly progressive form of cancer
that has been increasing in incidence. Patients may experience symptoms of
thickened, red, cracking, scaling or intensely itchy skin in localized areas
or all over the body. About 10 percent of patients will have blood, lymph
node and/or internal organ involvement with serious complications. Many
patients live normal lives during treatment and some are able to remain in
remission for long periods of time. There is a greater frequency among men
than women and CTCL is more common after the age of 50.

For more complete information on indications, contraindications, warnings
and precautions, see the Instructions for Use available at:
http://www.therakos.com

About THERAKOS (TM)

Therakos, Inc., focuses on immune cell therapies. Based in Ascot in the
United Kingdom and in Exton, Pennsylvania, in the United States, THERAKOS(TM)
markets the only approved integrated systems for extracorporeal
photopheresis.

Source: Therakos, Inc

Media Contact: Teresa Mueller, +33-1-5500-4433, tmueller1@jnjfr.jnj.com

-------
Profile: Transplant News